Introduction on hPSC-CMS {#S1}
========================

Nearly two decades since their first description ([@B43]), hPSC-CMs are beginning to fulfill their potential as a reductionist model of the human cardiac muscle. Thanks to constant improvements in differentiation protocols ([@B71]; [@B49]; [@B120]; [@B42]; [@B53]; [@B9]) and increasing understanding of their *in vitro* cardiac phenotype, hPSC-CMs are now an integral part of proposed high-throughput drug screening ([@B45]; [@B22]) and drug risk-assessment platforms ([@B121]; [@B56]; [@B52]). Furthermore, there is evidence for their increasing reliability in predicting adverse drug effects ([@B6]).

The successful induction of pluripotency in human somatic cells ([@B101]; [@B122]; [@B55]; [@B80]) opened the cardiac field to patient-specific disease modeling ([@B13]; [@B70]), although patient-specific treatment modeling still remains an open challenge ([@B7]). The race toward generating mutation-specific *in vitro* models produced \>150 independent hiPSC lines over the past 10 years and hundreds of scientific papers frequently and comprehensively reviewed ([@B86]; [@B111]; [@B110]). Consequently, there is a clear literature unbalance against non-genetic cardiac pathology models, often coming with additional challenges in recreating *in vitro* either the pathological phenotype, the pathological environment or both ([Figure 1](#F1){ref-type="fig"}).

![Non-genetic pathological conditions leading to heart failure. **(A)** The three main pathological conditions discussed in this review are schematically represented, highlighting the major molecular drivers and pathological phenotypes that need to be reproduced *in vitro* in order to generate a representative and reliable pathology model. **(B)** Main experimental strategies employed to generate pathological phenotypes in non-genetic cardiac disease models *in vitro*. For detailed experimental protocols employed in the reviewed studies, see [Supplementary Materials](#DS1){ref-type="supplementary-material"}.](fphys-11-00384-g001){#F1}

Here, we discuss modeling of non-genetic heart conditions, focusing exclusively on results obtained on human cells when the referenced study makes only sparing use of hPSC-CMs

Advantages and Limitations {#S2}
==========================

Inter-species differences are a major concern in translational research. Therefore, the human origin paired with virtually unlimited low-cost supply constitute the most valuable advantages of hPSC-CMs. Beyond the most often quoted heart size, beating rate, electrophysiology and protein function ([@B74]; [@B31]), more subtle differences are apparent also in stress-responses. For instance, an *in vitro* angiotensin-II-induced heart failure model reproduces the appearance observed in failing myocardia of two loss-of-function Na~*V*~1.5 channel isoforms produced by abnormal *SCN5A* splicing through a mechanism absent in species other than primates ([@B26], [@B27]). Such response contributes to the sodium current reduction in angiotensin-II-treated hPSC-CMs, mimicking pro-arrhythmic conditions in failing ventricles ([@B66]). Similarly, evolutionarily closer species display divergent transcriptomic responses to ischemia-mimetic environments, with rhesus macaque monkey PSC-CMs failing to overlap results with hPSC-CMs at gene regulation level ([@B126]), and chimpanzee PSC-CMs still diverging in regulation of critical genes tightly related to human ischemia/reperfusion pathogenesis ([@B115]).

Although hPSC-CMs can develop full adult phenotypes, these have been achieved so far only by integration within healthy animal myocardia ([@B16]; [@B40]), and hPSC-CM developmental immaturity is seen as their major drawback. We ([@B62]) and others ([@B109]) have shown that transcriptomic profiling places hPSC-CMs within the first trimester of fetal development, with structural, functional and metabolic features further supporting such characterization ([@B59]).

Nevertheless, unprimed hPSC-CMs (no maturation protocol applied) still represent a valid reductionist model in dissecting molecular mechanisms within human and cardiac cell backgrounds. For instance, a recent study successfully identified direct inactivation mechanisms of human voltage-sensitive L-type calcium channels by molecular O~2~ and acidosis ([@B21]), complementing our findings in murine models ([@B63]). Simultaneously, the authors clearly show how studying more complex functional features requires careful evaluation of cardiac structural maturation, with whole-cell ion dynamics changing following substrate interaction, which our group showed to be mediated by mechanotransduction signaling ([@B64]).

Additionally, taking advantage of developmentally early phenotypes of hPSC-CM and hijacking the differentiation process from hPSCs allows modeling developmental defects leading to postnatal pathological conditions. Such is the case of hypoplastic left heart syndrome in a chronic-hypoxia model ([@B25]), which preceded patient-specific hPSC-CMs models ultimately identifying the underlying genetic-driven molecular mechanisms ([@B37]; [@B46]; [@B104]; [@B34]; [@B119]). Similarly, hPSC-CMs were used to model the role of the mitochondrial calcium uniporter in cardiac fetal development and maturation ([@B99]). Finally, although chemically induced cardiotoxicity will not be a subject of this review \[see ([@B60])\], one recent study considered the impact of ethanol on hPSC-CM functionality as a model of prenatal exposure during maternal alcohol intoxication ([@B83]).

Maladaptive Hypertrophy Modeling {#S3}
================================

The developmentally early phenotype of hPSC-CMs provides additional complexity in modeling hypertrophy *in vitro*, with differentiation/maturation phenomena blurring distinctions between physiological and pathological hypertrophy. Physiological hypertrophic growth is a cardiac perinatal maturation process, reactivated in adulthood upon regular physical activity, and differs substantially from pathological (or maladaptive) hypertrophy in activation mechanisms and elicited functional responses ([@B67]). For instance, the evaluation of cell-size increase must be performed carefully, being an ambivalent hallmark for both processes ([@B87]), and appears to be absent in advanced maturation stages ([@B84]). Similarly ambivalent is the application of mechanical stretch, which simultaneously induces hypertrophic responses and promotes hPSC-CM maturation ([@B48]), generating phenotypes divergent from pathological neurohormonal stimulation relative to αMHC/βMHC transcription activation ratios ([@B24]) or CathepsinD/TroponinT release ([@B33]).

Chronic adrenergic activation is one of the pathogenic triggers of maladaptive hypertrophy, and the effects of prolonged exposure to isoproterenol or phenylephrine have been studied in hPSC-CMs in regard to hypertrophy-inhibiting effects of several active compounds ([@B24]; [@B65]; [@B28]). Nevertheless, the reliability of this approach is hindered by hPSC-CM immature adrenergic signaling ([@B39]; [@B108]; [@B105]), which generates highly variable and aberrant stress-responses ([@B23]) often failing to produce representative pathological phenotypes *in vitro* ([@B102]; [@B17]; [@B72]).

Hormonal stimulation has been shown to be more effective for maladaptive hypertrophy modeling purposes, with angiotensin-II and especially endothelin-1 treatments successfully recapitulating hypertrophic phenotypes in terms of expression/secretion of natriuretic peptides A and B ([@B12]), myofibrillar disarray ([@B102]) and mRNA/miRNA profiling ([@B3]). Such a model has been dually employed thus far to study the molecular mechanisms of maladaptation *in vitro* ([@B17]; [@B85]), and evaluate anti-hypertrophic effects of miRNAs ([@B94]), herbal extracts ([@B125]) and antiparasitic compounds ([@B82]), for which hPSC-CMs are superior to murine cardiac cell lines lacking in expression of several key target proteins ([@B73]).

Alternatively to being employed as *in vitro* hypertrophy modeling platform, hPSC-CMs have proven useful in experimentally confirming observations made in human and murine hypertrophic heart biopsies of the involvement of non-coding RNAs in maladaptive pathogenesis ([@B114]; [@B68]).

Ischemia/Reperfusion Injury Modeling {#S4}
====================================

Ischemia is the most dramatic of cardiac insults, leading to or aggravating pre-existing stages of heart failure. The nature of the pathological stressors (a composite of fast dynamic changes in nutrients, waste products, O~2~ and ROS) makes cellular responses and pathological fallouts tightly connected to adult cardiomyocyte metabolic processes, elevating hPSC-CM maturation to a necessity for modeling purposes.

Indeed, several studies describe little or no response to I/R-mimetic conditions in unprimed hPSC-CMs, although showing minimal but relatively significant cardioprotection by the individual molecules of interest ([@B35]; [@B116]; [@B69]). Our own experiments with oxygen/glucose deprivation in microfluidic devices show clearly divergent responses of postnatal murine cardiomyocytes and unprimed hPSC-CMs characterized by abnormal intracellular glycogen stores ([@B61]). Similar experimental setups have been used to study the mechanistic action of anesthetics ([@B57]) and miRNA-based regulation of metalloproteases ([@B94]).

Recent studies demonstrate how developing a stress-responsive phenotype must be set as an essential element in a feasible hPSC-CM model for I/R studies. Priming hPSC-CMs through simple maturation steps generates cells responsive to I/R with mortality rates unseen in their unprimed counterparts, ultimately providing the biological model needed to test clinically effective small molecules ([@B32]) or investigate the cardioprotective mechanism of cardiac progenitors ([@B96]). The most intriguing example of *in vitro* I/R modeling to date fully embraces hPSC-CMs as platform for both drug screening and development ([@B22]). The researchers identify MAP4K4 as a druggable target, activity of which is altered across several clinically relevant heart failure models, and employ an I/R setup with primed hPSC-CMs to screen for suitable small-molecule inhibitors. After using the identified lead-compound to develop a *novel* inhibitor, they ultimately translate the cardioprotective properties of a small-molecule newly developed in hPSC-CMs to an *in vivo* murine model of ischemic insult.

Diabetes Modeling {#S5}
=================

Similar to ischemia models, replicating diabetic pathophysiology *in vitro* requires primed hPSC-CMs as starting point. While underlying genetic factors might further its severity, prolonged exposure to altered metabolic stimuli is the leading trigger and driving force of the clinical manifestations of diabetic cardiomyopathy ([@B30]). Indeed, an I/R model that linked anesthetic-conferred cardioprotection to pharmacological tuning of mitochondrial function in hPSC-CMs ([@B97]; [@B11]) produced no differences between diabetic patient-specific cells and healthy controls. Both showed equal abrogation of protection under acute hyperglycemic conditions, thus failing to replicate the clinical differences between healthy and diabetic surgery patients ([@B10]).

On the other hand, when allowed to adapt to prolonged exposure to hyperglycemic stress, hPSC-CMs develop pathological hypertrophy characterized by contractile and calcium cycling dysfunctions ([@B75]). Capitalizing on this phenotype has enabled investigations into mechanisms behind unexpected clinical trial evidence of empagliflozin-driven reduction of deadly cardiovascular complications in diabetic patients. Similar approaches of metabolic overload with fatty acids allow the induction of insulin-resistance and dissection of its mechanism in hPSC-CMs ([@B14]; [@B54]; [@B30]).

Primed hPSC-CMs develop a complete panel of diabetic cardiomyopathy phenotypes by integrating metabolic overload conditions with additional hormonal stimulation abnormally present in the diabetic milieu ([@B36]; [@B38]), proven by aggravated contractile dysfunction following endothelin-1 stimulation ([@B118]). A complete set of stressors (metabolic overload, endothelin-1 and cortisol treatment) recapitulates *in vitro* hypertrophic-like transcriptomic changes, increased BNP secretion, compromised calcium cycling and contraction, lipid accumulation and oxidation, sarcomeric disorganization ([@B20]), insulin-resistance and reduced respiratory capacity ([@B30]), and deregulated non-coding RNAs expression ([@B79]). Satisfying all of these conditions in such a multifactorial pathological setting provides the necessary platform for drug-screening experiments and is instrumental in revealing underlying differences between healthy and patient-derived hPSC-CMs ([@B20]).

Other Pathology Models {#S6}
======================

Hypertrophy, ischemia/reperfusion and diabetes are conditions with major economic and social impacts. Nevertheless, hPSC-CMs have been also employed in modeling less common pathological settings, such as systemic pathogen infections leading to myocarditis and heart failure. Modeling septic shock by exposure to bacterial lipopolysaccharides affects hPSC-CM survival, electrophysiology and demonstrates their competence in activating innate immune inflammatory responses ([@B123]). Indeed, hPSC-CM display stronger macrophage chemo-attractant properties than purified chemokines ([@B78]) and significant stress-responsive paracrine pro-inflammatory signaling ([@B95]) mediating fibrosis *in vivo* and *in vitro* ([@B47]; [@B124]). Furthermore, functional expression of coxsackievirus and adenovirus receptor ([@B93]) makes hPSC-CMs a better predictive model than murine cardiac cell lines for therapeutic approaches against viral myocarditis ([@B100]). Similarly, hPSC-CMs are a viable host for parasites causing Chagas disease ([@B18]; [@B8]) and, consequently, a good screening platform for novel drugs preventing infection and major cardiac fallouts of the pathology ([@B91], [@B92]).

Spaceflight-associated stressors such as radiation and microgravity induce cardiac atrophy and arrhythmias, increasing cardiovascular complication rates in astronauts ([@B1]). Thus far, the intrinsic challenges of hPSC-CM aerospace applications limit *in vitro* models to phenotypic descriptions, orphan of underlying molecular mechanisms. Microgravity modeling, for instance, has been performed only twice on human PSC-CMs, observing increases in beating rate under acute conditions during parabolic flight ([@B1]) and mainly transcriptomic changes during chronic exposure onboard the International Space Station ([@B117]). Although studied relative to anti-cancer treatment, radiation-induced heart disease is another astronaut concern, and hPSC-CMs respond to ionizing radiations in dose-dependent manner with electrophysiological ([@B5]) and transcriptomic ([@B4]) alterations.

Disease Modeling With 3D Constructs {#S7}
===================================

hPSC-CM maturation *in vitro* is relatively fast in comparison with *in vivo* development, supporting the idea that these mechanisms differ substantially. Thus, modeling non-genetic pathologies mostly originating from insults to the adult heart in the late stages of cardiac development is within reach of 1,2 month-long cultures. While originally proposed as a maturation mechanism ([@B90]; [@B77]; [@B41]; [@B58]), extended time in culture was recently extensively characterized over a 4-month period showing expression of aging markers in unprimed hPSC-CMs and increased sensitivity to I/R in disorganized 3D aggregates ([@B2]). To date, human engineered heart tissues (hEHTs) provide the closest match to an adult cardiomyocyte phenotype *in vitro* ([@B103]; [@B84]).

hEHTs assemble hPSC-CMs into 3D constructs integrating multifactorial stimuli such as electrophysiological pacing ([@B50]; [@B127]), mechanical loading ([@B51]), ECM structure ([@B29]) and non-myocyte cell interactions ([@B112]). Such constructs, in their immature state, have been proposed as models to study human cardiac self-regenerative potential after localized injury ([@B113]), and produce structurally and metabolically primed hPSC-CMs when allowed to develop further, even in absence of additional stimuli ([@B107]).

A recent hEHT I/R model showed for the first time in human cells the cardioprotective effect of ischemic preconditioning and efficacy of one out of three proposed cardioprotection treatments for reperfusion injury ([@B15]). Nevertheless, similar hEHTs generated by pure hPSC-CM populations are limited in their maturation potential ([@B81]) and limit the study of the complex bidirectional crosstalk of multiple cell types, important during ischemic stress *via* paracrine signaling ([@B89]; [@B96], [@B95]) and neurohormonal stimulation. The latter can be effectively modeled solely with hEHTs, as 2D cultures lack or display functionally impaired a β-adrenergic signaling cascades ([@B39]; [@B108]; [@B105]), despite being able to form functional sympathetic neuro-junctions ([@B88]). Indeed, chronic exposure of hEHTs to norepinephrine induces contractile dysfunction and β-adrenergic desensitization, which with additional endothelin-1-driven hypertrophic stimulation, generates an advanced model of heart failure ([@B103]). Notably, endothelin -1 treatment does not produce additional hypertrophic growth in hPSC-CM at such late stages of maturation, but induces more clinically relevant hypertrophic features, such as contractile dysfunction ([@B84]). Additionally, porcine scaffold-based hEHTs have been employed recently to highlight the vicious cycle of maladaptive hypertrophy, with healthy hPSC-CMs responding to hypertrophic ECMs with impaired function, which *in vivo* would feed-back to the cardiac microenvironment triggering additional maladaptation preventing recovery under pharmacological treatment ([@B98]).

Conclusion and Future Perspectives {#S8}
==================================

Animal-derived models often incorrectly represent human cardiac features and diverge in stress-responses ([@B76]; [@B19]). hPSC-CMs offer an invaluable tool to study the human heart *in vitro*, provided that stress-responsive phenotypes are apparent and representative of *in vivo* conditions. The necessity of hPSC-CM priming for pathology modeling is apparent in some hereditary monogenic pathologies ([@B44]), but becomes essential for most non-genetic diseases described here, given their incidence later in adult life. Optimization of cardiac maturation and metabolic priming protocols generated better insight into the crosstalk between structural, functional and metabolic states of hPSC-CMs. These advances now allow more representative modeling of non-genetic diseases, still lagging behind the highly penetrant genetic conditions with clear analytical read-outs that dominate hPSC-CM literature ([Figure 2A](#F2){ref-type="fig"}).

![Literature statistics on cardiac pathology models and cited references. **(A)** Complete representation of pathological models for cardiac diseases available on PubMed between January 1st 2018 and January 2nd 2020. HCM, Hypertrophic Cardiomyopathy; DCM, Dilated Cardiomyopathy; AC, Arrhythmogenic Cardiomyopathy; L/SQTS, Long/Short QT Syndrome; CPVT, Catecholaminergic Polymorphic Ventricular Tachycardia; BS, Brugada Syndrome; AF, Atrial Fibrillation; DYS, Muscular Dystrophies \[Duchenne (9), Myotonic (4), Limb-Girdle (1)\]; FRDA, Friedriech's Ataxia; FD, Fabry Disease; DD, Danon Disease; NS, Noonan Syndrome; Other, different genetic diseases represented by (1) article. *Inset*: all cardiac genetic pathology models reported in 2018--2019 relative to cell model derivation. "Lab engineered": healthy hPSC genetically edited to carry the mutation under consideration. **(B)** Representation of non-genetic conditions referenced in this review according to the pathological condition modeled. *Inset*: distribution *per* year of publication of the referenced articles (same color coding). For bibliographical research methods and full list of references reported in this figure, see [Supplementary Material](#DS1){ref-type="supplementary-material"}.](fphys-11-00384-g002){#F2}

Currently, advanced modeling of the adult myocardium requires hEHTs. These multiparametric setups integrating stimulation and data acquisition systems, act as human preclinical models refining the predictive efficacy of less throughput-limited 2D hPSC-CM models ([@B22]). Nevertheless, while closely resembling adult tissue transcriptomic and functional features, hEHTs fall short of gaining the status of full-fledged *organoids*, not fully mimicking adult myocardial macroscopic ultrastructure ([@B103]; [@B84]), thus requiring additional bioengineering efforts to scale up the systems from tissue- to organ-models, as the recently proposed atrioventricular composite ([@B127]).

Importantly, the widespread use of commercially available cell products in the studies reported here ([Supplementary Table S1](#DS1){ref-type="supplementary-material"}) highlights the necessity of increasing robustness and reproducibility of the results through differentiation and culture protocols standardization. Indeed, whenever patient-specificity is not essential, employment of standardized experimental platforms is desirable to study a plethora of environmental cardiac insults ([@B106]; [Figure 2B](#F2){ref-type="fig"}), remaining mindful of the pitfalls of broadening the results of few cell lines to the general population and of the aspirations toward personalized medicine approaches.

Finally, combining hPSC-CM-based models with high precision genome-editing technologies will be instrumental in not only supporting modeling of hereditary diseases by screening artificially introduced genetic variants of unknown significance (VUSs) ([Figure 2A](#F2){ref-type="fig"}), but also in dissecting complex dynamics between non-genetic pathological stimuli and genetic backgrounds characterized by polygenic interactions.
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